Analyzing Ocular Therapeutix (OCUL) and C.R. Bard (BCR)

Ocular Therapeutix (NASDAQ: OCUL) and C.R. Bard (NYSE:BCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.


This table compares Ocular Therapeutix and C.R. Bard’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix -3,241.19% -126.31% -81.51%
C.R. Bard 14.75% 48.28% 16.23%

Analyst Ratings

This is a summary of recent ratings for Ocular Therapeutix and C.R. Bard, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix 0 2 4 0 2.67
C.R. Bard 0 7 0 0 2.00

Ocular Therapeutix presently has a consensus price target of $20.67, suggesting a potential upside of 454.07%. C.R. Bard has a consensus price target of $295.43, suggesting a potential downside of 12.06%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than C.R. Bard.

Volatility and Risk

Ocular Therapeutix has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, C.R. Bard has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ocular Therapeutix and C.R. Bard’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Ocular Therapeutix $1.89 million 58.10 -$44.70 million ($2.28) -1.64
C.R. Bard $3.71 billion 6.59 $531.40 million $7.59 44.26

C.R. Bard has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than C.R. Bard, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.0% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 80.3% of C.R. Bard shares are owned by institutional investors. 26.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 0.8% of C.R. Bard shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. Ocular Therapeutix does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. C.R. Bard has increased its dividend for 45 consecutive years.


C.R. Bard beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

C.R. Bard Company Profile

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with's FREE daily email newsletter.

Leave a Reply